|
Subject: tow-cross-over med. At Visit 2, each HV received a single dose of 0.125 mg pramipexole IR. Subsequently, each HV was treated with four different ER tablets (C containing pre-gelatinised starch, C2 containing maize starch, C2A: 20% faster release than C2, and C2B: 20% slower release than C2) containing 0.375 mg pramipexole ER. Formulation C2 was given in tow-cross-over periods (at fasted and fed state).
|
| You need to be logged in to post in the forum |